SERES THERAPEUTICS
Seres Therapeutics is a clinical-stage biotherapeutic company that develops ecobiotic therapeutic products. They engaged in developing biological drugs which are referred to as ecobiotic microbiome therapeutics.
SERES THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.serestherapeutics.com
Total Employee:
251+
Status:
Active
Contact:
+1 617 945 9626
Email Addresses:
[email protected]
Total Funding:
402.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Nginx Sitelinks Search Box
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
NextCure
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Seres Therapeutics
CARB-X
CARB-X investment in Grant - Seres Therapeutics
Nestlé Health Science
Nestlé Health Science investment in Series D - Seres Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Series C - Seres Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Series B - Seres Therapeutics
Alexandria Venture
Alexandria Venture investment in Series B - Seres Therapeutics
Enso Ventures
Enso Ventures investment in Series B - Seres Therapeutics
Mayo Clinic
Mayo Clinic investment in Series B - Seres Therapeutics
Enso Ventures
Enso Ventures investment in Series A - Seres Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Series A - Seres Therapeutics
Newest Events participated
Participated in South Summit 2017
on 2017-10-04 as sponsor
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-08 | Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer |
Official Site Inspections
http://www.serestherapeutics.com Semrush global rank: 1.94 M Semrush visits lastest month: 11.12 K
- Host name: 14.165.188.35.bc.googleusercontent.com
- IP address: 35.188.165.14
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Seres Therapeutics"
About Us - Seres Therapeutics
From 1998 to 2007, she served as president and director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies. Dr. …See details»
Our Platform - Seres Therapeutics
Our in-house manufacturing organization integrates process development, current Good Manufacturing Practices (cGMP), Quality Control and Quality Assurance. These capabilities …See details»
MANAGEMENT TEAM - Seres Therapeutics
Michele (Shelley) Trucksis, Ph.D., M.D. is the Executive Vice President and Chief Medical Officer of Seres Therapeutics. She formerly served as Executive Director of Merck Research …See details»
Seres Therapeutics - LinkedIn
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first ...See details»
Seres Therapeutics and Nestlé Health Science Announce FDA …
Apr 26, 2023 Accompanying slides will be posted on the Seres website prior to the call. To access the conference call, please dial 773-305-6867 (domestic) or 866-400-0049 …See details»
Seres Therapeutics - Crunchbase Company Profile
Seres Therapeutics may be growing as evidenced by reports of encouraging sales growth and strategic cost savings in 2023. The company has reported preliminary Q4 sales of $10.4 million, which is a positive indicator of revenue …See details»
Seres Therapeutics Presents Microbiome Therapeutic Research at …
Jun 1, 2022 For more information, please visit www.serestherapeutics.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the …See details»
Inside Seres - Seres Therapeutics
At Seres, we’re leading the microbiome revolution — and our most revolutionary asset is our team. We’re courageous and deeply collaborative, and above all we’re passionate about the commitment we’ve made to blaze a new trail for …See details»
NHSc announce ser-109 co-commercialization license …
Jul 1, 2021 To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 5382249. To join the live webcast, please visit the “Investors and News” …See details»
Seres Therapeutics Enters Into Memorandum of Understanding …
Jun 6, 2024 Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure …See details»
Seres Therapeutics Announces First Patient Enrolled in Phase 1b …
Nov 30, 2021 The World Health Organization has declared antibiotic resistant infections a “top ten” global public health threat and according to the Center for Disease Control’s Antibiotic …See details»
Seres Therapeutics Reports First Quarter 2023 Financial Results …
May 9, 2023 To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference Conference ID 5098595. To join the live webcast, please …See details»
Our Programs - Seres Therapeutics
Mechanism of action. SER-155 is a multifunctional consortium of commensal bacteria designed based on human clinical insights. SER-155 is designed to augment the following microbiome …See details»
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 …
CAMBRIDGE, Mass., March 05, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial …See details»
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled …
Sep 12, 2024 The conference call may be accessed by calling 1-800-715-9871 (international callers dial 1-646-307-1963) and referencing the conference ID number 622932. To join the …See details»
Patients and Physicians - Seres Therapeutics
Seres has published data for the Phase 3 ECOSPOR III study for the prevention of recurrent C. difficile in the New England Journal of Medicine.. Clostridioides difficile, formerly known as …See details»
Seres Therapeutics Company Profile - Office Locations ... - Craft
Seres Therapeutics has 5 employees at their 1 location and $126.33 m in annual revenue in FY 2023. See insights on Seres Therapeutics including office locations, competitors, revenue, …See details»
Seres Therapeutics Reports Second Quarter 2021 Financial Results …
Aug 3, 2021 To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 6519859. To join the live …See details»
Annual Reports - Seres Therapeutics
The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.See details»